UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
(Amendment No. 7)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
POINT Biopharma Global Inc.
(Name of Subject Company)
POINT Biopharma Global Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
730541109
(CUSIP Number of Class of Securities)
Joe McCann
Chief Executive Officer
4850 West 78th Street
Indianapolis, IN
(317) 543-9957
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
With copies to:
Graham Robinson Chadé Severin Skadden, Arps, Slate, Meagher & Flom LLP 500 Boylston Street, 23rd Floor Boston, Massachusetts 02116 (617) 573-4800 |
| ☐ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 7 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, the “Schedule 14D-9”) filed by POINT Biopharma Global Inc., a Delaware corporation (“POINT”) with the Securities and Exchange Commission on October 13, 2023, relating to the tender offer by Yosemite Falls Acquisition Corporation, a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Eli Lilly and Company, an Indiana corporation (“Lilly”), to purchase all of the issued and outstanding shares of common stock of POINT, par value $0.0001 per share (the “Shares”), at a purchase price of $12.50 per Share, net to the stockholder in cash, without interest, and less any applicable tax withholding, on the terms and subject to the conditions set forth in the Offer to Purchase, dated as of October 13, 2023 (as amended or supplemented from time to time) and the related Letter of Transmittal (as amended or supplemented from time to time), and pursuant to the Agreement and Plan of Merger, dated as of October 2, 2023, by and among Lilly, Purchaser and POINT.
Except to the extent specifically provided in this Amendment, the information set forth in the Schedule 14D-9 remains unchanged. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to them in the Schedule 14D-9. This Amendment No. 7 is being filed to reflect certain updates as set forth below.
ITEM 2. IDENTITY AND BACKGROUND OF FILING PERSON
Item 2 of the Schedule 14D-9 is hereby amended and supplemented as follows:
| 1. | By adding the bold and underlined text and deleting the struck through text to the below paragraph under the subsection titled “Tender Offer” on page 3 as follows: |
“Purchaser commenced (within the meaning of Rule 14d-2 promulgated under the Exchange Act) the Offer on October 13, 2023. The Offer was initially scheduled to expire at one minute after 11:59 p.m., Eastern Time, on November 9, 2023. On November 8, 2023, the Offer was extended until 5:00 p.m., Eastern Time, on November 16, 2023. On November 17, 2023, the Offer was extended until 5:00 p.m., Eastern Time, on December 1, 2023. On December 4, 2023, the Offer was extended until 5:00 p.m., Eastern Time, on December 15, 2023. On December 18, 2023, Lilly announced a further extension of the Offer until 5:00 p.m., Eastern Time, on December 15December 22, 2023 (the “Expiration Time”), unless the expiration of the Offer is extended to a subsequent date in accordance with the terms of the Merger Agreement, in which case the term “Expiration Time” means such subsequent time on such subsequent date. The depositary has advised Purchaser that, as of 5:00 p.m., Eastern Time, on December 1 December 15, 2023, approximately 26,374,912 24,338,647 Shares had been validly tendered into and not properly withdrawn pursuant to the Offer, representing approximately 24.75% 22.81% of the outstanding Shares. If at the scheduled Expiration Time any of the conditions to the Offer (other than the Minimum Tender Condition) have not been satisfied or waived, Purchaser shall, and Lilly shall cause Purchaser to, extend the Offer for one or more consecutive increments of not more than 10 business days each (or such longer period as may be agreed to by Lilly and POINT), until such time as such conditions have been satisfied or waived. Purchaser shall, and Lilly shall cause Purchaser to, extend the Offer for the minimum period required by any rule, regulation, interpretation or position of the SEC or the staff thereof or The Nasdaq Capital Market, in each case that are applicable to the Offer. In addition, if at the scheduled Expiration Time, each condition to the Offer (other than the Minimum Tender Condition) shall have been satisfied or waived and the Minimum Tender Condition shall not have been satisfied, Purchaser may elect to (and if so requested by POINT, Purchaser shall, and Lilly shall cause Purchaser to), extend the Offer for one or more consecutive increments of such duration as requested by POINT (or if not so requested by POINT, as determined by Lilly), but not more than 10 business days each (or for such longer period as may be agreed to by Lilly and POINT), provided that POINT shall not request Purchaser to, and Lilly shall not be required to cause Purchaser to, extend the Offer pursuant to this sentence on more than five occasions. In no event will Purchaser be required to extend the Offer beyond one minute after 11:59 p.m., Eastern Time, on July 2, 2024 (the “Outside Date”), provided that the Outside Date may be extended once by a period of 90 days, if on the Outside Date all of the Offer Conditions have been satisfied or waived by Lilly or Purchaser (other than conditions that by their nature are to be satisfied at the Acceptance Time, each of which is then capable of being satisfied), other than the Antitrust Condition, the NRC Condition and the condition requiring the absence of any Legal Restraint by any Specified Governmental Entity preventing or prohibiting the consummation of the Offer or the Merger.”
2
ITEM 8. ADDITIONAL INFORMATION
Item 8 of the Schedule 14D-9 is hereby amended and supplemented as follows:
| 1. | By adding the following new subsection and paragraph immediately following the end of the subsection titled “Legal Proceedings” on page 44 as follows: |
“SPLASH Clinical Trial Topline Data Announcement
On December 18, 2023, POINT and Lantheus announced topline results of the SPLASH Clinical Trial. A copy of the press release announcing the results is filed as Exhibit (a)(5)(N) to this Schedule 14D-9.”
3
ITEM 9. EXHIBITS
| 1. | Item 9 is hereby amended and supplemented by adding the following exhibits: |
Exhibit No. | Description | |
| (a)(5)(N) | Joint Press Release issued by POINT and Lantheus on December 18, 2023. | |
| (a)(5)(O) | Press Release issued by Lilly on December 18, 2023 (incorporated by reference to Exhibit (a)(5)(F) to the Schedule TO). | |
4
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: December 18, 2023
| POINT Biopharma Global Inc. | ||||
| By: | /s/ Bill Demers | |||
| Name: | Bill Demers | |||
| Title: | Chief Financial Officer | |||
